Our new SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with sensitivity equivalent to our OncoBEAM digital PCR liquid biopsy from across a broader range of genomic regions.
OncoBEAM set the gold standard for ctDNA analysis as the most sensitive digital PCR approach available.(1) It has been used to detect subclonal resistance mutations, such as those in ESR1 for breast cancer patients on adjuvant aromatase inhibitor therapy who demonstrate endocrine resistance.(2)
With robust detection as low as 0.03%* mutant allele frequency (MAF), SafeSEQ ensures reliable molecular information for real-time therapy selection as well as monitoring of tumor response.
The data in the figure below shows the robust accuracy at low allelic frequencies observed for SafeSEQ and demonstrates the advantages of using focused panels for defined clinical purposes.(3)
*For input of 20,000 genomic equivalents
SafeSEQ sensitivity has 99.2% agreement with OncoBEAMTM
Ultra-sensitive SafeSEQ Panels
A liquid biopsy solution for the identification of mutations in PIK3CA, ESR1, AKT1, ERBB2, TP53, and KRAS to detect established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations.Learn More
A liquid biopsy solution for the identification of gene mutations associated with Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD).Learn More
Head and Neck Cancer
A liquid biopsy solution for the identification of mutations in CDKN2A, EGFR, ERBB2, FGFR3, HRAS, KRAS, NOTCH1, PIK3CA, PTEN, and TP53 associated with Head and Neck Squamous Cell Cancer (HNSCC).Learn More
A liquid biopsy solution for the identification of mutations in KRAS, NRAS, BRAF, PIK3CA, and AKT1 associated with colorectal cancer minimal residual disease and recurrence.Learn More
A liquid biopsy solution for the identification of mutations in AKT1, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, and TP53 associated with Non-Small Cell Lung Cancer (NSCLC).Learn More
Liquid biopsy solution for the identification of mutations in KRAS, NRAS, BRAF, PIK3CA, and AKT1 to inform therapy selection, determine therapeutic efficacy, monitor disease dynamics, and detect disease recurrence.Learn More
NGS-based assay for the detection and quantification of human papillomavirus (HPV) DNA in cancers caused by two high-risk strains of HPV, HPV 16 and HPV 18. This test enables precise tracking of disease burden and response to therapy in patients with HPV-associated cancer.Learn More